The receipts.
Anyone can describe a cell as remarkable. This page is the part that is checkable — the peer-reviewed literature, the patent position, the institutional collaborations, and the scientific advisory network behind the platform. Every claim here is traceable to a source you can open yourself.
Protected, not merely proprietary
Most regenerative material sold to clinics is a commodity. Anyone can source it, anyone can undercut it, and nothing stops the clinic down the road from offering the same thing next quarter. That is the economic reality of the category.
This platform is the exception. The trophoblast stem cell technology is covered by a patent estate of 54 granted patents worldwide across 12 distinct families, with a further 46 applications in process, as reported by the platform originator (2026-07). That is a composition-of-matter position, not a trade secret or a process claim.
For a provider clinic the consequence is straightforward: this is a durable position rather than a temporary advantage.
Composition-of-matter position
Published work on this lineage
Indexed in PubMed Central, the open archive maintained by the U.S. National Library of Medicine at the National Institutes of Health. Each entry links to the source. One of the four carries company co-authors; the other three are independent groups working on the same lineage.
The Secretome of Human Trophoblast Stem Cells Attenuates Senescence-Associated Traits
Aging Cell 25(2):e70368 · PMID 41521531 · in vitro, senescent WI-38 lung fibroblasts · NIA collaborative, includes company co-authors Open 2025Therapeutic impact of human trophoblast stem cells in peritoneal and pneumonia-induced sepsis in mice
Stem Cell Research & Therapy · preclinical, murine model · Brigham and Women's Hospital / Harvard Medical School, independent of the company · TSCs derived from term placenta, not the pre-implantation line Open 2023Regenerative capacity of trophoblast stem cell-derived extracellular vesicles on mesenchymal stem cells
Biomaterials Research · preclinical, includes skin wound model · Korea University Guro Hospital, independent of the company Open 2021Extracellular vesicles (secretomes) from human trophoblasts promote the regeneration of skin fibroblasts
International Journal of Molecular Sciences · in vitro, dermal fibroblasts · Korea University Guro Hospital, independent of the company OpenWho else has staked their name on it
The most useful signal about a platform is rarely what its owner says about it. It is who agrees to work with it, and what they were willing to announce publicly.
The Wistar Institute — research collaboration on hTSC-derived immune cell approaches
Philadelphia, USA · one of the oldest independent biomedical research institutes in the country Open PluristyxClinical-grade iPSC lines created by reprogramming the trophoblast source
Seattle, USA · the strongest external evidence of starting-material quality Open SupplyAvailability of clinical-grade immune-privileged hTSCs announced
Joint announcement · clinical-grade material availability Open StemmattersStrategic partnership advancing hTSC-derived iPSC development
Portugal · European development and commercialisation track OpenThe people who reviewed it
The scientific advisory board of the platform originator. Listed with the affiliations that make each of them worth listening to on this specific subject.
Chairman of the scientific advisory board. Discovered and characterised the human trophoblast stem cell line at Kaohsiung Medical University Hospital — the origin of the entire platform.
Founder of PanCella and former Director of the NIH Center for Regenerative Medicine. Among the most cited figures in the field's translation from laboratory to clinic.
President and Chief Science Officer of the LEV Foundation. One of the most widely recognised figures in longevity biology.
Founder of Pluristyx, previously at Johnson & Johnson. Directly involved in the clinical-grade iPSC work built on this source material.
Founder of Cartherics. Cell-based immunotherapy development.
Chief Executive of Bioceros. Developed the PER.C6 cell line at Crucell — one of the more consequential manufacturing cell lines in biologics.
Over twenty years in clinical research and development.
Advisory board members serve the platform originator. Listing an advisor's institutional history is a statement of their credentials and does not imply that any named institution endorses Infinity Cell or any product described on this site.
Where the platform sits in the field
Memberships and affiliations of the platform originator. Membership of a trade or scientific body indicates participation in that organisation and does not constitute endorsement, certification or approval of any product.